Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in ...

Finding an effective, safe medication to control itch is essential to maximize patient comfort. Because Zenrelia does not require a loading dose and is administered once daily, Zenrelia may help impro ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Ambient air pollution, hot and cold temperature extremes and other factors associated with climate change are likely ...

Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

New research suggests the lack of a bacterium known to help infants digest breast milk could have significant consequences ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...